Typbar-TCV®: Questions and answers

**TYPBAR-TCV**

**What is Typbar-TCV?**
Typbar-TCV is a typhoid conjugate vaccine (TCV) manufactured by Bharat Biotech. It contains purified Vi capsular polysaccharide of *Salmonella enterica* serovar Typhi Ty2 conjugated to a tetanus toxoid carrier protein.

**Who can receive Typbar-TCV?**
Typbar-TCV can be administered to adults, children, and infants 6 months of age and older.

**What is the dosage schedule for Typbar-TCV?**
Typbar-TCV is a one-dose vaccine. A single 0.5 mL dose injected intramuscularly, is expected to provide long-lasting protection in adults, children, and infants over 6 months of age.

**Is Typbar-TCV safe?**
The World Health Organization (WHO) has reviewed clinical trial results and determined that Typbar-TCV is safe and well-tolerated.

**Is Typbar-TCV effective?**
Interim results from a Phase 3 study conducted in Nepal found that a single dose of Typbar-TCV was safe and efficacious in an endemic setting, preventing 81.6 percent of typhoid cases among vaccinated children. Other studies have also shown that Typbar-TCV elicits a strong immune response in infants, children, and adults.

**Is Typbar-TCV prequalified by WHO?**
Typbar-TCV was prequalified by WHO in January 2018. This signifies that the vaccine meets stringent international standards and allows it to be purchased by United Nations agencies. It is an important step for inclusion in Gavi, the Vaccine Alliance’s investment strategy, which helps finance vaccine access in low-income countries.

**Which countries are using Typbar-TCV?**
Pakistan became the first country to introduce TCV into its routine immunization program in November 2019, beginning in Sindh Province. Liberia and Zimbabwe will introduce TCV into their routine immunization programs in 2020. Several other countries are in various stages of planning for introduction. The Typhoid Vaccine Acceleration Consortium (TyVAC) is conducting clinical trials with Typbar-TCV in four countries: Bangladesh, Burkina Faso, Malawi, and Nepal.

**Does Gavi support the introduction of Typbar-TCV?**
Gavi announced US$85 million in funding for eligible countries to introduce TCVs in 2019 and 2020, with applications open in 2018. Because Typbar-TCV is the first prequalified TCV, it is currently the only typhoid vaccine eligible for introduction in Gavi-supported countries.

**TYPHOID CONJUGATE VACCINES**

**What are TCVs?**
TCVs are made by linking the Vi capsular polysaccharide of the typhoid bacteria to a more complex protein. Through conjugation, TCVs are able to stimulate parts of the immune system that older typhoid vaccines cannot, thereby inducing a stronger, longer-lasting immunity among a broader age range.

**What are the benefits of TCVs?**
Compared to the Vi capsular polysaccharide and oral live attenuated typhoid vaccines, TCVs have longer-lasting protection, require fewer doses, and are suitable for children 6 months of age and older, allowing delivery through routine childhood immunization programs. Expanded use of TCVs through routine immunization has the potential to reduce the need for antibiotics, slow further emergence of drug-resistant typhoid strains, and save lives.

Learn more and join the effort at www.takeontyphoid.org.
#TakeOnTyphoid